The clinical trial will investigate the effect of different formulations of ARA + 0.4% DHA in
infant formula on plasma fatty acid status in healthy 6 months old infants supplemented for 6
months. A 6-month follow on phase will provide additional efficacy (e.g. infection rates,
immune markers) and safety information in these 12-18 month old infants.